[Clinical application of calcimimetics].

Calcimimetic agents modulate the activity of calcium-sensing receptor on the surface of parathyroid cell and suppress the secretion of parathyroid hormone. Several clinical trials demonstrated that the second-generation calcimimetics cinacalcet HCl reduced PTH level, as well as Ca x P product in secondary hyperparathyroidism, while the agents reduced PTH and calcium level in primary hyperparathyroidism.